NVIGEN X® Precision Medicine Biomarker Profiling
Cancer (Recurrence Prediction & Therapy Guidance)
Pre-clinicalActive
Key Facts
Indication
Cancer (Recurrence Prediction & Therapy Guidance)
Phase
Pre-clinical
Status
Active
Company
About NVIGEN
NVIGEN is a private, nanotechnology-focused biotech company developing a suite of products and assays centered on its patented MagVigen™ and related nanoparticle platforms. Its core business model spans Diagnostics and Platform tools, offering research-use products like magnetic beads for sample preparation while advancing its NVIGEN X® liquid biopsy assay toward clinical development for cancer recurrence prediction and therapy guidance. The company is in an Early Revenue stage, commercializing research kits and services while investing in its clinical pipeline, which is currently in the Pre-clinical/development phase.
View full company profile